MIM
BCRX icon

Macroview Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Macroview Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,132
Closed -$8.6K – 130
2024
Q3 		$8.6K Buy
+1,132
New +$8.61K 0.01% 293
2015
Q1 		– Sell
-100
Closed -$1K – 143
2014
Q4 		$1K Buy
+100
New +$1.1K ﹤0.01% 149

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Macroview Investment Management's BCRX Position: Q4 2024 in Review

Macroview Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 1,132 shares — an estimated $8.6K sold.

Macroview Investment Management first reported a position in BCRX in Q4 2014 and held it in 2 quarters. The position peaked at $8.6K in Q3 2024. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Macroview Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Macroview Investment Management sold 1,132 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $8.6K.
  • Macroview Investment Management first reported a position in BioCryst Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Macroview Investment Management's BioCryst Pharmaceuticals position peaked at $8.6K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Macroview Investment Management's 13F filing for Q4 2024, filed 31 Jan 2025.